PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 66.2357

Change

+0.64 (+0.97)%

Market Cap

N/A

Volume

0.01M

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-17 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+1.84 (+1.27%)

USD 37.98B
FHLC Fidelity® MSCI Health Care In..

+0.94 (+1.38%)

USD 2.70B
FXH First Trust Health Care AlphaD..

+1.73 (+1.67%)

USD 1.01B
XHE SPDR® S&P Health Care Equipme..

+1.51 (+1.83%)

USD 0.18B
IDNA iShares Genomics Immunology an..

+0.23 (+1.05%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

+0.57 (+1.85%)

USD 0.09B
XHS SPDR® S&P Health Care Service..

+1.67 (+1.75%)

USD 0.08B
HTEC Robo Global® Healthcare Techn..

+0.38 (+1.36%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

+1.41 (+2.35%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

+0.19 (+0.93%)

USD 6.67M

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -0.44% 33% F 47% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -0.44% 33% F 44% F
Trailing 12 Months  
Capital Gain 3.46% 67% D+ 54% F
Dividend Return 0.01% 6% D- N/A F
Total Return 3.47% 67% D+ 39% F
Trailing 5 Years  
Capital Gain 65.18% 52% F 47% F
Dividend Return 0.19% 11% F N/A F
Total Return 65.36% 48% F 36% F
Average Annual (5 Year Horizon)  
Capital Gain 4.32% 57% F 48% F
Dividend Return 4.34% 48% F 41% F
Total Return 0.02% 11% F 1% F
Risk Return Profile  
Volatility (Standard Deviation) 19.67% 48% F 55% F
Risk Adjusted Return 22.07% 52% F 37% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.